London
15 °C
Manchester
16 °C
Glasgow
15 °C
Dublin
Belfast
14 °C
Washington
Denver
Atlanta
Dallas
Houston Texas
New Orleans
El Paso
Phoenix
Los Angeles
22 °C
1 °C
26 °C
3 °C
16 °C
27 °C
Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts
NYSE - LSE
| CMSC | -0.62% | 24.1 | $ | |
| SCS | 0.24% | 16.94 | $ | |
| RIO | -0.31% | 63.451 | $ | |
| BCE | 0.11% | 23.095 | $ | |
| BCC | -0.62% | 78.95 | $ | |
| CMSD | -0.45% | 24.35 | $ | |
| RYCEF | 0.63% | 15.75 | $ | |
| NGG | -0.04% | 70.93 | $ | |
| RBGPF | 0% | 76.6 | $ | |
| JRI | 0.43% | 14.06 | $ | |
| BTI | -1.98% | 52.825 | $ | |
| VOD | -0.35% | 11.35 | $ | |
| GSK | -1.02% | 40.495 | $ | |
| RELX | -1.25% | 46.5 | $ | |
| AZN | -1.84% | 76.1 | $ | |
| BP | 1.88% | 35.03 | $ |
Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts
SAN FRANCISCO, CA / ACCESS Newswire / September 23, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday, September 25, 2025 at the Emerging Growth Conference and virtually on Tuesday, September 30, 2025 at the Lytham Partners Fall 2025 Conference.
Participation Instructions for Jaguar's Virtual Presentation at the Emerging Growth Conference
When: Thursday, September 25, 2025 from 2:55 - 3:05 PM Eastern Time
Where: Online (Click Here)
Registration link for conference: Click Here
Replay: An archived webcast of the presentation will be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel.
Participation Instructions for Jaguar's Virtual Presentation at the Lytham Partners Fall 2025 Conference
When: Tuesday, September 30, 2025 at 3:30 PM Eastern Time
Where: Online (Click Here). A replay of the webcast will be available through the same link.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Canalevia-CA1, visit canalevia.com
Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that Jaguar management will present at the September 2025 Emerging Growth Conference and the Lytham Partners Fall 2025 Conference. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
CONTACT:
[email protected]
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire
W.Richard--SMC
